HN2301 for autoimmune diseases study
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old.
- You have been diagnosed with lupus, scleroderma, or rheumatoid arthritis and have been on a stable treatment for at least 8 weeks.
- You have normal or near-normal blood counts, liver and kidney function, and heart and lung function.
- You are not pregnant or breastfeeding and agree to use birth control for 12 months after treatment.
- You must not have had a major organ transplant or received any mRNA or LNP medication in the past 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medicine called HN2302 in people with certain autoimmune diseases like lupus or scleroderma. The goal is to see if it is safe and if it can help reduce disease activity, which might improve symptoms.
This trial tests a new cell therapy called SNC116 for people with lupus that has not improved with standard treatments. The treatment aims to reset the immune system to reduce disease activity and may help those with severe lupus or kidney inflammation.
This study tests a new drug called HBM7020 to see if it is safe and how well it is absorbed by the body. It is for healthy people and people with certain autoimmune diseases like lupus, scleroderma, rheumatoid arthritis, or Sjögren's disease.
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.